Investor Presentaiton

Investor Presentation First nine months of 2018 Sales per key product for Q3 2018 and the first nine months of 2018 Slide 112 Reported currencies Sales Q3 2018 (mDKK) Sales split Sales 9M 2018 (mDKK) Sales split TresibaⓇ 2,156 8% 5,863 7% LevemirⓇ NovoRapidⓇ 2,560 9% 8,363 13% 4,445 16% 13,939 18% NovoMix® 2,332 8% 7,241 9% VictozaⓇ 6,115 22% 17,833 20% OzempicⓇ 540 2% 804 0% SaxendaⓇ 987 4% 2,640 2% Diabetes care and obesity¹ 23,366 84% 66,367 83% NovoSevenⓇ 1,885 7% 5,925 8% NorditropinⓇ 1,688 6% 4,872 6% Biopharmaceuticals¹ 4,396 16% 13,092 17% Total¹ 27,762 100% 82,099 100% 1 Values are higher than the sum of the total elements listed due to residual values from products not listed 9M: First nine months of 2018 changing diabetes novo nordisk

View entire presentation